Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology
Pharmaceutics · 21.01.2025 · 17 (2) · 142
DOI: 10.3390/pharmaceutics17020142 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 21.01.2025. Verfasst von Miguel Horta und 3 weiteren Autor:innen. Beteiligte Einrichtung: i3S-Instituto de Investigação e Inovação em Saúde, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 203 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia (FCT), Consórcio PORTO.CCC-Porto. Comprehensive Cancer Center Raquel Seruca, Institute for Research and Innovation in Health Sciences.
Abstract (Originalsprache)
Glioblastoma’s (GB) complex tumor microenvironment (TME) promotes its progression and resistance to therapy. A critical component of TME is the extracellular matrix (ECM), which plays a pivotal role in promoting the tumor’s invasive behavior and aggressiveness. Nanotechnology holds significant promise for GB treatment, with the potential to address challenges posed by both the blood-brain barrier and the GB ECM. By enabling targeted delivery of therapeutic and diagnostic agents, nanotechnology offers the prospect of improving treatment efficacy and diagnostic accuracy at the tumor site. This review provides a comprehensive exploration of GB, including its epidemiology, classification, and current treatment strategies, alongside the intricacies of its TME. It highlights nanotechnology-based strategies, focusing on nanoparticle formulations such as liposomes, polymeric nanoparticles, and gold nanoparticles, which have shown promise in GB therapy. Furthermore, it explores how different emerging nanotechnology strategies modulate the ECM to overcome the challenges posed by its high density, which restricts drug distribution within GB tumors. By emphasizing the intersection of nanotechnology and GB ECM, this review underscores an innovative approach to advancing GB treatment. It addresses the limitations of current therapies, identifies new research avenues, and emphasizes the potential of nanotechnology to improve patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- i3S-Instituto de Investigação e Inovação em Saúde, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
- IPATIMUP-Instituto de Patologia e Imunologia Molecular, University of Porto, Rua Júlio Amaral de Carvalho 45, 4200-135 Porto, Portugal.
- FMUP-Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
- INEB-Instituto Nacional de Engenharia Biomédica, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
ORCID-Profile: Paula Soares, Catarina Leite Pereira, Raquel T Lima
Förderung
- Fundação para a Ciência e Tecnologia (FCT)
- Consórcio PORTO.CCC-Porto. Comprehensive Cancer Center Raquel Seruca
- Institute for Research and Innovation in Health Sciences
- The Porto Comprehensive Cancer Center
Zitieren
APA
Horta, M., Soares, P., Leite Pereira, C., & Lima, R. T. (2025). Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology. Pharmaceutics, 17(2), 142. https://doi.org/10.3390/pharmaceutics17020142
Vancouver
Horta M, Soares P, Leite Pereira C, Lima RT. Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology. Pharmaceutics. 2025;17(2):142. doi:10.3390/pharmaceutics17020142
BibTeX
@article{Horta2025,
author = {Horta, Miguel and Soares, Paula and Leite Pereira, Catarina and Lima, Raquel T},
title = {Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {2},
pages = {142},
doi = {10.3390/pharmaceutics17020142}
}
EUVIMED